The University of Texas System

Massachusetts Institute of Technology

Radiomedix Inc.

Ali Azhdarinia

David J Yang

Dong-Fang Yu

Nathaniel L Wilganowski

E Edmund Kim

Chang-Sok Oh

Saady Kohanim

Sukhen C Ghosh

Changsok Oh

Firas Mourtada

Ebrahim S Delpassand

Izabela Tworowska

Dongfang Yu

Jennifer Sims-Mourtada

Mithu Chanda

Tommy L Lee

Jerry Bryant

Chang Sok Oh

In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

Multifunctional linker technology containing an N4 group

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

Compositions for targeted imaging and therapy

The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving Ncompounds and derivatives.

Compositions and methods for cellular imaging and therapy

Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X&#x2014;Y&#x2014;X, wherein Y comprises two or more carbohydrate residues covalently attached to one another, Xand Xare diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, Xand Xare diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.

Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications

Compositions for imaging pancreatic beta cells comprise chelator-antidiabetic agent conjugates and optionally chelated metals.

Mechanism-based targeted pancreatic beta cell imaging and therapy

The present invention provides automated systems for the purification of radioisotopes, the formulation of radiopharmaceuticals or both. In preferred embodiments the radioisotopes are produced by a generator. In further preferred embodiments the automated systems comprise replaceable cassettes for easy replacement of the system's networks of tubing. Also provided are replaceable cassettes and kits for use with the automated systems of the invention. The invention further provides methods of using an automated system to purify radioisotopes, formulate radiopharmaceuticals or to do both in series.

Automated system for formulating radiopharmaceuticals

Methods regarding local regional treatment in situ for an individual, such as of a tumor, are provided herein. A hydrogel composition is generated in situ in the tumor by administering a polymer, such as a polysaccharide or a polyamino acid, with a therapeutic agent, such as a radionuclide or a drug, and administering a cross-linking agent. The hydrogel/therapeutic agent composition is retained in the tumor for safe and efficient tumor therapy. Alternatively, a hydrogel composition is generated in situ in an artery which nourishes a tumor to occlude the artery.

Local regional chemotherapy and radiotherapy using in situ hydrogel

Growing community of inventors

Houston, TX, United States of America

Ali Azhdarinia